憑藉簡化的法規環境,包括對 IND 無任何規定,以及在臨床研究支出上,有支持研發的政府退還金高達 43.5% ,讓澳洲成為早期臨床試驗的首選目的地。
過去幾年來,澳洲的臨床試驗案件數穩定成長,在 2016 年至 2018 年期間每年成長超過 10%。
Featured media on Novotech’s leadership and impact.
Expert insights and real-world perspectives.
In-depth perspectives on forces shaping clinical research.
Tracking science and trends across therapeutic areas.
Hear from experts shaping clinical development.
Conversations with leaders shaping drug development.
A global CRO and scientific partner advancing drug development.
Our impact extends beyond trials, shaping healthier futures worldwide.
A collaborative, science-driven approach.
Recognized for excellence across the industry.
Decades of clinical and scientific leadership.
A global clinical research leader with an award-winning culture.
A culture that empowers growth, innovation, and impact.
Explore career opportunities at Novotech.
Benefits and recognition that support your success.
Experts collaborating to advance clinical research.
A commitment to your growth and development.
憑藉簡化的法規環境,包括對 IND 無任何規定,以及在臨床研究支出上,有支持研發的政府退還金高達 43.5% ,讓澳洲成為早期臨床試驗的首選目的地。
過去幾年來,澳洲的臨床試驗案件數穩定成長,在 2016 年至 2018 年期間每年成長超過 10%。